Skip to Content


It’s Time to Sell

March 21, 2012, 5:30 pm

Now THIS is my idea of fun!

On the heels of last week’s sell alert (locking in an 85% gain in Ariad Pharmaceuticals and a 33% gain in Novo Nordisk), I just told my readers to lock in their 55% profit on Mako Surgical.

Three big winners in one week—and there is plenty more ahead as our GameChangers continue to pound ahead of the market.

If you didn’t take me up on my offer to get on board with our next round of healthcare and biotech winners, it’s not too late.

This week’s market breather is giving you the perfect opportunity to snap them up ahead of the next big leg up.

Get on board with one of my top three healthcare and biotech GameChangers today for our next round of 35%-80% gains from:

  • The company fighting America’s #1 killer. 80 million Americans have some form of cardiovascular disease. And 620,000 of us die each year from it.

Those numbers are expected to soar in the next 20 years as 72 million baby boomers head into their golden years.

The game-changing stock I’m recommending now will be at the forefront of these advances. It’s an innovator in its field, is a proven developer of products that meet unmet needs, and is positioned to benefit from growth of one of the most critical medical industries.

I’ve discovered two overlooked items in their financials that I think can give the stock an extra boost in the months ahead.

I believe the company’s earnings guidance is UNDERstated relative to the cash they are generating. They also have a very high 38% tax rate baked in, and I think that tax-loss carry forwards will likely reduce that amount.

Both could lead to a nice earnings surprise that will boost the stock.

Looking a little longer-term, with strong cash flow, high margins and a very solid balance sheet, this small player should attract suitors like bees to honey.

It all adds up to an exciting chance to pocket 40% or more in the coming months.

  • A health care stock with game-changing technology and a long track record of developing innovative (and often indispensable) products for a high-growth industry. With big margins and a rock-solid balance sheet, this small company would make a GREAT acquisition target. Get on board before a competitor swoops in and scoops it up.
  • A small biotech company with an unparalleled pipeline stocked with at least 8 new drugs in clinical or preclinical development. Thanks to an explosion in economic prosperity, increased government spending on drugs, and a massive unmet need, China is one of the fastest-growing pharmaceutical markets on the planet. It is projected to grow an unheard-of 25% a year for the next 10 years!

This game-changing biotech firm is making a mint providing this huge market with powerful drugs at a fraction of the cost American companies do.

Just reported exciting fourth-quarter earnings. Exports nearly quadrupled, revenue grew 45%. You don’t want to miss this one!

Get the full details on these three stocks, as well as all the stocks on my current buy list, with a risk-free trial to GameChangers. Learn how to try it for a full six months with my 100% money back guarantee here.

Be the first to leave a comment.

* Required. Email address will not be shared.

By submitting a comment you grant Kramer Capital Research a perpetual license to reproduce your words and name/web site in attribution. Inappropriate and irrelevant comments will be removed at an admin’s discretion. Your email is used for verification purposes only, it will never be shared. Please note that comments will be not be responded to directly on this website, but may be addressed through future articles and other content.